Article info
PDFMultiple sclerosis
Review
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- Correspondence to Dr Christopher McGuigan, Department of Neurology, St Vincent's University Hospital, Elm Park, Dublin 4, & University College Dublin, Dublin Dublin 4, Ireland; c.mcguigan{at}st-vincents.ie
Citation
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
Publication history
- Received April 20, 2015
- Revised September 2, 2015
- Accepted September 25, 2015
- First published October 22, 2015.
Online issue publication
April 13, 2016
Article Versions
- Previous version (13 April 2016).
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
- Data supplement 1 - Online supplement
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/